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Objectives
Cost data for trial-based economic evaluation can be
obtained through micro-costing (collecting resource use
and unit cost data for each centre or patient), gross-
costing (average costs based on top-line budgets) or pro-
vider tariffs (e.g. healthcare resource groups, HRGs).
Most studies use a combination of approaches due to
data availability, although there is little guidance on
which is best. We report a systematic comparison of the
three costing approaches in IVAN: a non-inferiority ran-
domised controlled factorial trial of treatment regimens
for age-related macular degeneration (AMD), where pol-
icy makers are interested in the efficacy and cost-effec-
tiveness of two dosing regimens of bevacizumab
(Avastin) and ranibizumab (Lucentis). We aimed to
assess the extent to which micro-costing, gross-costing
and HRGs differ, and to investigate resource use varia-
tion between UK hospitals and explore possible reasons
for this variability.
Methods
We compared micro-costing, gross-costing and HRG
estimates of consultation costs using IVAN data. Nine-
teen IVAN trial centres were sent questionnaires on the
resources required to set up and run clinics. Resources
were valued using national unit costs to give micro-cost-
ing estimates that are compared against Department of
Health gross-costing estimates and the HRG for
ophthalmology outpatient consultations. Regression ana-
lyses explore the variability between centres.
Results
Fourteen centres (74%) returned questionnaires. The
mean cost of a follow-up ophthalmology outpatient
consultation is £74 compared with an HRG cost of £53.
Preliminary micro-costing suggests that both HRGs and
gross-costs substantially underestimate the cost of con-
sultations to administer treatment (excluding drug
costs) or monitor outcomes. Micro-costing also high-
lighted substantial variation in consultation costs, facil-
ities, organisation and resource use not captured within
HRGs or gross-costs. Clinic size did not explain varia-
tions in consultation costs.
Conclusions
Although data analysis is ongoing, initial results sug-
gest that micro-costing estimates for administration
and monitoring of Avastin/Lucentis are higher than
gross-costs or HRGs. HRG costs were lowest, suggest-
ing that hospitals must cut costs substantially to break
even on such consultations. Differences in costing
methodology are likely to affect cost-effectiveness
results: particularly in the context of a non-inferiority
trial comparing different dosing regimens, where cost
differences will drive conclusions about cost-effective-
ness. Only micro-costing differentiated between con-
sultations for monitoring and drug administration.
Micro-costing (unlike other approaches) also showed
how costs and patient management vary between UK
centres, facilitating analysis of heterogeneity and iden-
tification of potential efficiency improvements. This
demonstrates the value of collecting detailed resource
use data in trials.
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